company background image
TECH

Bio-Techne NasdaqGS:TECH Stock Report

Last Price

US$284.00

Market Cap

US$11.1b

7D

-2.4%

1Y

-42.5%

Updated

02 Oct, 2022

Data

Company Financials +
TECH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance5/6
Financial Health6/6
Dividends0/6

TECH Stock Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.

Bio-Techne Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bio-Techne
Historical stock prices
Current Share PriceUS$284.00
52 Week HighUS$531.80
52 Week LowUS$281.42
Beta1.25
1 Month Change-13.95%
3 Month Change-19.59%
1 Year Change-42.49%
3 Year Change41.01%
5 Year Change131.72%
Change since IPO10,982.93%

Recent News & Updates

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Let's talk about the popular Bio-Techne Corporation ( NASDAQ:TECH ). The company's shares saw significant share price...

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Sep 01

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Bio-Techne (NASDAQ:TECH) said it plans to seek shareholder approval at its upcoming 2022 annual meeting to implement a four-for-one stock split in the form of a stock dividend. Following approval, Bio-Techne's board intends to declare the stock split and set a record date and distribution date for the stock dividend, the company added in a Sept. 1 press release. The stock dividend is expected to occur in the company's Q2 of fiscal 2023.

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

TECHUS Life SciencesUS Market
7D-2.4%-1.9%-2.5%
1Y-42.5%-32.0%-23.2%

Return vs Industry: TECH underperformed the US Life Sciences industry which returned -31.9% over the past year.

Return vs Market: TECH underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is TECH's price volatile compared to industry and market?
TECH volatility
TECH Average Weekly Movement4.7%
Life Sciences Industry Average Movement9.7%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: TECH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: TECH's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19763,000Chuck Kummethhttps://www.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
TECH fundamental statistics
Market CapUS$11.14b
Earnings (TTM)US$271.93m
Revenue (TTM)US$1.11b

41.0x

P/E Ratio

10.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TECH income statement (TTM)
RevenueUS$1.11b
Cost of RevenueUS$347.51m
Gross ProfitUS$758.09m
Other ExpensesUS$486.16m
EarningsUS$271.93m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)6.93
Gross Margin68.57%
Net Profit Margin24.60%
Debt/Equity Ratio15.1%

How did TECH perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

18%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is TECH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TECH?

Other financial metrics that can be useful for relative valuation.

TECH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue10.1x
Enterprise Value/EBITDA31.2x
PEG Ratio3.8x

Price to Earnings Ratio vs Peers

How does TECH's PE Ratio compare to its peers?

TECH PE Ratio vs Peers
The above table shows the PE ratio for TECH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average21.6x
CRL Charles River Laboratories International
22.6x17.8%US$10.0b
QGEN Qiagen
18.3x7.9%US$9.4b
AVTR Avantor
23.1x20.0%US$13.2b
PKI PerkinElmer
22.5x3.9%US$15.2b
TECH Bio-Techne
41x10.8%US$11.1b

Price-To-Earnings vs Peers: TECH is expensive based on its Price-To-Earnings Ratio (41x) compared to the peer average (21.6x).


Price to Earnings Ratio vs Industry

How does TECH's PE Ratio compare vs other companies in the US Life Sciences Industry?

Price-To-Earnings vs Industry: TECH is expensive based on its Price-To-Earnings Ratio (41x) compared to the US Life Sciences industry average (23.2x)


Price to Earnings Ratio vs Fair Ratio

What is TECH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TECH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio41x
Fair PE Ratio24x

Price-To-Earnings vs Fair Ratio: TECH is expensive based on its Price-To-Earnings Ratio (41x) compared to the estimated Fair Price-To-Earnings Ratio (24x).


Share Price vs Fair Value

What is the Fair Price of TECH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TECH ($284) is trading below our estimate of fair value ($422.37)

Significantly Below Fair Value: TECH is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Bio-Techne forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TECH's forecast earnings growth (10.8% per year) is above the savings rate (1.9%).

Earnings vs Market: TECH's earnings (10.8% per year) are forecast to grow slower than the US market (14.8% per year).

High Growth Earnings: TECH's earnings are forecast to grow, but not significantly.

Revenue vs Market: TECH's revenue (11.5% per year) is forecast to grow faster than the US market (7.7% per year).

High Growth Revenue: TECH's revenue (11.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TECH's Return on Equity is forecast to be high in 3 years time (20.9%)


Discover growth companies

Past Performance

How has Bio-Techne performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


19.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TECH has high quality earnings.

Growing Profit Margin: TECH's current net profit margins (24.6%) are higher than last year (15.1%).


Past Earnings Growth Analysis

Earnings Trend: TECH's earnings have grown by 19.9% per year over the past 5 years.

Accelerating Growth: TECH's earnings growth over the past year (93.8%) exceeds its 5-year average (19.9% per year).

Earnings vs Industry: TECH earnings growth over the past year (93.8%) exceeded the Life Sciences industry 15.6%.


Return on Equity

High ROE: TECH's Return on Equity (15.5%) is considered low.


Discover strong past performing companies

Financial Health

How is Bio-Techne's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: TECH's short term assets ($605.6M) exceed its short term liabilities ($176.0M).

Long Term Liabilities: TECH's short term assets ($605.6M) exceed its long term liabilities ($417.8M).


Debt to Equity History and Analysis

Debt Level: TECH's net debt to equity ratio (0.6%) is considered satisfactory.

Reducing Debt: TECH's debt to equity ratio has reduced from 36.2% to 15.1% over the past 5 years.

Debt Coverage: TECH's debt is well covered by operating cash flow (126.9%).

Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (28.5x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Bio-Techne current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.45%

Current Dividend Yield

Dividend Yield vs Market

Bio-Techne Dividend Yield vs Market
How does Bio-Techne dividend yield compare to the market?
SegmentDividend Yield
Company (Bio-Techne)0.4%
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Life Sciences)0.3%
Analyst forecast in 3 Years (Bio-Techne)0.5%

Notable Dividend: TECH's dividend (0.45%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).

High Dividend: TECH's dividend (0.45%) is low compared to the top 25% of dividend payers in the US market (4.73%).


Stability and Growth of Payments

Stable Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: TECH is not paying a notable dividend for the US market.


Cash Payout to Shareholders

Cash Flow Coverage: TECH is not paying a notable dividend for the US market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Chuck Kummeth (62 yo)

9.5yrs

Tenure

US$15,370,548

Compensation

Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M...


CEO Compensation Analysis

Chuck Kummeth's Compensation vs Bio-Techne Earnings
How has Chuck Kummeth's remuneration changed compared to Bio-Techne's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022US$15mUS$1m

US$272m

Mar 31 2022n/an/a

US$225m

Dec 31 2021n/an/a

US$210m

Sep 30 2021n/an/a

US$177m

Jun 30 2021US$16mUS$1m

US$140m

Mar 31 2021n/an/a

US$184m

Dec 31 2020n/an/a

US$175m

Sep 30 2020n/an/a

US$248m

Jun 30 2020US$11mUS$1m

US$229m

Mar 31 2020n/an/a

US$187m

Dec 31 2019n/an/a

US$195m

Sep 30 2019n/an/a

US$93m

Jun 30 2019US$11mUS$957k

US$96m

Mar 31 2019n/an/a

US$121m

Dec 31 2018n/an/a

US$96m

Sep 30 2018n/an/a

US$128m

Jun 30 2018US$10mUS$911k

US$126m

Mar 31 2018n/an/a

US$112m

Dec 31 2017n/an/a

US$114m

Sep 30 2017n/an/a

US$73m

Jun 30 2017US$9mUS$880k

US$76m

Mar 31 2017n/an/a

US$74m

Dec 31 2016n/an/a

US$82m

Sep 30 2016n/an/a

US$101m

Jun 30 2016US$7mUS$800k

US$104m

Compensation vs Market: Chuck's total compensation ($USD15.37M) is about average for companies of similar size in the US market ($USD13.04M).

Compensation vs Earnings: Chuck's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: TECH's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: TECH's board of directors are considered experienced (9.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGS:TECH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 May 22BuyUS$105,765Robert BaumgartnerIndividual300US$352.55

Ownership Breakdown

What is the ownership structure of TECH?
Owner TypeNumber of SharesOwnership Percentage
Private Companies6580.002%
State or Government16,9990.04%
Individual Insiders305,1890.8%
General Public1,007,7712.6%
Institutions37,881,41696.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 63.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.37%
The Vanguard Group, Inc.
4,460,345$1.3b0.34%0.03%
10.93%
BlackRock, Inc.
4,287,606$1.2b-2.64%0.03%
4%
State Street Global Advisors, Inc.
1,568,279$445.4m-1.74%0.03%
3.7%
Baron Capital Group, Inc.
1,451,376$412.2m-1.21%1.14%
3.37%
Select Equity Group, L.P.
1,321,431$375.3m89.19%1.38%
2.67%
Neuberger Berman Investment Advisers LLC
1,045,789$297.0m-2.66%0.3%
2.14%
Brown Capital Management, LLC
839,587$238.4m-8.57%2.6%
2.01%
Geode Capital Management, LLC
786,834$223.5m0.17%0.03%
1.74%
D.F. Dent and Company, Inc.
684,026$194.3m-0.36%2.91%
1.69%
Winslow Capital Management, LLC
663,100$188.3m449.58%1.23%
1.67%
Eaton Vance Management
656,643$186.5m-1.18%0.07%
1.67%
Mairs and Power, Inc.
655,930$186.3m-0.31%2.29%
1.67%
Ownership Capital B.V.
655,654$186.2m-21.96%3.28%
1.63%
Wellington Management Group LLP
638,373$181.3m39.71%0.03%
1.58%
Columbia Management Investment Advisers, LLC
620,904$176.3m-0.85%0.05%
1.42%
Jackson Square Partners, LLC
556,157$157.9m-4.23%3.81%
1.37%
BNY Mellon Asset Management
536,876$152.5m2.27%0.04%
1.28%
Fred Alger Management, LLC
501,778$142.5m-39.36%0.67%
1.26%
Champlain Investment Partners, LLC
493,595$140.2m-0.78%0.93%
1.22%
Allspring Global Investments, LLC
477,834$135.7m-5.39%0.21%
1.21%
Massachusetts Financial Services Company
474,852$134.9m-13.06%0.04%
1.14%
Marshall Wace LLP
448,038$127.2m60.52%0.35%
1.06%
Northern Trust Global Investments
413,918$117.6m-6.21%0.02%
0.98%
Mackenzie Financial Corporation
385,997$109.6m34.37%0.14%
0.96%
Macquarie Investment Management Business Trust
375,302$106.6m0.93%0.12%

Company Information

Bio-Techne Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Techne Corporation
  • Ticker: TECH
  • Exchange: NasdaqGS
  • Founded: 1976
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$11.136b
  • Shares outstanding: 39.21m
  • Website: https://www.bio-techne.com

Number of Employees


Location

  • Bio-Techne Corporation
  • 614 McKinley Place N.E.
  • Minneapolis
  • Minnesota
  • 55413
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TECHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1989
TE1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1989
TECH *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNFeb 1989
T1CH34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 30 REPR 1 COM NPVBRBRLOct 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/02 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.